KYMR
- Kymera Therapeutics, Inc.
()
Overview
Company Summary
Kymera Therapeutics, Inc., or KYMR, is a biopharmaceutical company that focuses on developing targeted protein degradation therapies. Their mission is to deliver breakthrough medicines for patients with serious diseases by harnessing the body's natural protein degradation system.
The company's approach is centered around targeting specific disease-causing proteins and eliminating them from the body. They utilize a proprietary technology platform called Pegasus�, which combines small molecule drug discovery with the ubiquitin-proteasome system (UPS) to selectively degrade disease-causing proteins.
Using their platform, Kymera designs and develops small molecules called degraders that can bind to disease-causing proteins, marking them for destruction by the body's natural protein degradation system. These degraders can target proteins that are considered undruggable by traditional approaches.
Kymera Therapeutics aims to address a wide range of diseases, including but not limited to oncology, immunology, and neurodegenerative disorders. By targeting specific proteins involved in these diseases, they aim to provide more effective and safer treatment options for patients.
The company collaborates with various organizations, including academic institutions, biotechnology companies, and pharmaceutical companies, to accelerate the development of their protein degrader therapies. Through these collaborations and their internal research efforts, Kymera is actively involved in advancing drug candidates into clinical trials and bringing innovative, targeted therapies to market.